Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
With
Breast Cancer Research Foundation
Roche Pharma AG
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with locally advanced, histologically confirmed adenocarcinoma of the female breast. Women with ulcerated breast lesions may be enrolled. Patients with asymptomatic metastases to the bone are eligible.
Ability to provide written informed consent prior to study-specific screening procedures
TNM Stage:T3-4, N0-3 M0; Patients with asymptomatic bone metastases may be enrolled. Patients with large T2 tumors whose surgeons believe their results with breast conserving surgery will be improved by neoadjuvant therapy may be enrolled.
Age 18 years or older
Negative serum or urine pregnancy test within 7 days prior to starting therapy (female patients of childbearing potential).
Performance status 0-1
Required Initial Laboratory Data:
Granulocytes \>=1,200/µl
Platelet count \>=100,000/µl
Calculated Creatinine Clearance \> 30 mL/min
Total bilirubin \<= Upper Limit Normal
Alkaline Phosphatase \<=Upper Limit Normal
SGPT, SGOT \<=Upper Limit Normal
Normal chest x-ray
You may not be if
HER2 positive breast cancer
Pregnant or lactating woman
Life expectancy \< 3 months
Serious, uncontrolled, concurrent infection(s)
Any prior fluoropyrimidine therapy or other chemotherapy
Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hyper-sensitivity to 5-fluorouracil or known DPD deficiency.
Patients who have received more than four weeks of tamoxifen therapy for this malignancy.
Treatment for other carcinomas within the last five years, except cured non- melanoma skin and treated in-situ cervical cancer.
Participation in any investigational drug study within 4 weeks preceding the start of study treatment.
Evidence of metastatic disease to sites other than the bone or with symptomatic bone lesions.
Other serious uncontrolled medical conditions that the investigator feels might compromise study participation.
Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
Known, existing uncontrolled coagulopathy or concurrent treatment with Coumadin and Phenytoin
Any of the following laboratory values:
Abnormal hematologic values (neutrophils \< 1.0 x 109/L, platelet count \< 100 x 109/L)
Impaired renal function (estimated creatinine clearance \<30ml/min as calculated with Cockcroft-Gault equation)
Serum bilirubin \> upper normal limit.
SGOT, SGPT \> upper normal limit
Clareo Health | Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
